Regenerex Pharma (RGPX) Gains from Sales and Divestitures (2023 - 2025)

Regenerex Pharma (RGPX) has 3 years of Gains from Sales and Divestitures data on file, last reported at $10.6 million in Q3 2025.

• Quarterly Gains from Sales and Divestitures rose 265.1% year-over-year to $10.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $10.6 million (up 265.1% YoY) and the FY2025 annual result came in at $5.7 million, up 120.13% from the prior year.
• Gains from Sales and Divestitures grew to $10.6 million in Q3 2025 per RGPX's latest filing, from $5.9 million in the prior quarter.
• Across five years, Gains from Sales and Divestitures topped out at $10.6 million in Q3 2025 and bottomed at $2.2 million in Q3 2023.
• The 3-year median for Gains from Sales and Divestitures is $2.9 million (2024), against an average of $4.6 million.
• The widest annual swing landed in 2024, when Gains from Sales and Divestitures jumped 31.31%; it then jumped 265.1% in 2025.
• Tracing RGPX's Gains from Sales and Divestitures over 3 years: stood at $2.4 million in 2023, then advanced by 22.68% to $2.9 million in 2024, then jumped by 265.1% to $10.6 million in 2025.
• Per Business Quant, the three latest RGPX Gains from Sales and Divestitures figures stand at $10.6 million (Q3 2025), $5.9 million (Q2 2025), and $5.7 million (Q1 2025).

Peer Comparison